Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
Clin Microbiol Infect ; 25(11): 1364-1369, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30771529

RESUMEN

BACKGROUND: Adjunctive systemic antibiotic therapy for treatment of bacterial endophthalmitis is controversial but common practice due to the severity of the disease. In the absence of guidance documents, several antibiotic regimens are being used without applying evidence-based prescribing, leading to inappropriate treatment of this serious eye condition. OBJECTIVES: To summarize available data on intravitreal penetration of systemically administered antibiotics and to discuss their usefulness from a microbiological and pharmacological point of view. SOURCES: We performed a systematic PubMed search of studies investigating antibiotic concentrations in the vitreous after systemic administration in humans, and selected animal models. CONTENT: The best-documented agents achieving therapeutic levels in the vitreous are meropenem, linezolid and moxifloxacin. Vancomycin, cefazoline, ceftriaxone, ceftazidime, imipenem and trimethoprim-sulfamethoxazole reach levels justifying their use in specific situations. Available data do not support the use of ciprofloxacin, levofloxacin, aminoglycosides, aminopenicillins, piperacillin, cefepime and clarithromycin. With very limited but available promising data, the use of daptomycin and rifampicin deserves further investigation. IMPLICATIONS: The choice of the adjunctive systemic antibiotic agent-in situations where it is considered relevant for treatment-must to date be made on an individual basis, considering microbiological aspects as well as operative status and inflammation of the eye. This review gives a systematic overview of antibiotic options and provides guidance to the clinician striving for optimal systemic antibiotic treatment of bacterial endophthalmitis.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Infecciones Bacterianas/tratamiento farmacológico , Endoftalmitis/tratamiento farmacológico , Cuerpo Vítreo/química , Administración Intravenosa , Animales , Modelos Animales de Enfermedad , Humanos
2.
Clin Microbiol Infect ; 24(11): 1214.e1-1214.e4, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-29909005

RESUMEN

OBJECTIVES: Echinocandins represent the first-line treatment of candidaemia. Acquired echinocandin resistance is mainly observed among Candida albicans and Candida glabrata and is associated with FKS hotspot mutations. The commercial Sensititre YeastOne™ (SYO) kit is widely used for antifungal susceptibility testing, but interpretive clinical breakpoints are not well defined. We determined echinocandins epidemiological cut-off values (ECV) for C. albicans/glabrata tested by SYO and assessed their ability to identify FKS mutants in a national survey of candidaemia. METHODS: Bloodstream isolates of C. albicans and C. glabrata were collected in 25 Swiss hospitals from 2004 to 2013 and tested by SYO. FKS hotspot sequencing was performed for isolates with an MIC≥ECV for any echinocandin. RESULTS: In all, 1277 C. albicans and 347 C. glabrata were included. ECV 97.5% of caspofungin, anidulafungin and micafungin were 0.12, 0.06 and 0.03 µg/mL for C. albicans, and 0.25, 0.12 and 0.03 µg/mL for C. glabrata, respectively. FKS hotspot sequencing was performed for 70 isolates. No mutation was found in the 52 'limit wild-type' isolates (MIC=ECV for at least one echinocandin). Among the 18 'non-wild-type' isolates (MIC>ECV for at least one echinocandin), FKS mutations were recovered in the only two isolates with MIC>ECV for all three echinocandins, but not in those exhibiting a 'non-wild-type' phenotype for only one or two echinocandins. CONCLUSION: This 10-year nationwide survey showed that the rate of echinocandin resistance among C. albicans and C. glabrata remains low in Switzerland despite increased echinocandin use. SYO-ECV could discriminate FKS mutants from wild-type isolates tested by SYO in this population.


Asunto(s)
Antifúngicos/farmacología , Candida albicans/genética , Candidiasis/microbiología , Farmacorresistencia Fúngica , Equinocandinas/farmacología , Candida glabrata , Equinocandinas/administración & dosificación , Humanos , Pruebas de Sensibilidad Microbiana , Mutación , Vigilancia de la Población , Suiza/epidemiología
4.
Eur J Clin Microbiol Infect Dis ; 37(7): 1231-1240, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29218468

RESUMEN

Cryptococcal meningitis (CM) is mostly seen in immunocompromised patients, particularly human immunodeficiency virus (HIV)-positive patients, but CM may also occur in apparently immunocompetent individuals. Outcome analyses have been performed in such patients but, due to the high prevalence of HIV infection worldwide, CM patients today may be admitted to hospitals with unknown HIV status, particularly in underdeveloped countries. The objective of this multicenter study was to analyze all types of CM cases in an aggregate cohort to disclose unfavorable outcomes. We retrospectively reviewed the hospitalized CM patients from 2000 to 2015 in 26 medical centers from 11 countries. Demographics, clinical, microbiological, radiological, therapeutic data, and outcomes were included. Death, neurological sequelae, or relapse were unfavorable outcomes. Seventy (43.8%) out of 160 study cases were identified as unfavorable and 104 (65%) were HIV infected. On multivariate analysis, the higher Glasgow Coma Scale (GCS) scores (p = 0.021), cerebrospinal fluid (CSF) leukocyte counts > 20 (p = 0.038), and higher CSF glucose levels (p = 0.048) were associated with favorable outcomes. On the other hand, malignancy (p = 0.026) was associated with poor outcomes. Although all CM patients require prompt and rational fungal management, those with significant risks for poor outcomes need to be closely monitored.


Asunto(s)
Antifúngicos/uso terapéutico , Meningitis Criptocócica/tratamiento farmacológico , Meningitis Criptocócica/mortalidad , Adulto , Líquido Cefalorraquídeo/microbiología , Comorbilidad , Cryptococcus/clasificación , Cryptococcus/aislamiento & purificación , Femenino , Infecciones por VIH/complicaciones , Humanos , Huésped Inmunocomprometido , Masculino , Meningitis Criptocócica/diagnóstico , Persona de Mediana Edad , Estudios Retrospectivos , Encuestas y Cuestionarios , Resultado del Tratamiento
5.
Bone Marrow Transplant ; 50(4): 573-8, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25599166

RESUMEN

The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). We determined the incidence and the prognostic significance of HZ and its correlation with VZV serology in 191 consecutive myeloma patients undergoing high-dose melphalan chemotherapy with ASCT. We found that VZV reactivation occurred in 57 (30%) patients, in 8.5% during induction and in 21.5% after ASCT peaking at 8 months after ASCT. Disease burden due to HZ was assessed as high or rather high in 70% of the patients. By immune fluorescence and Serion Elisa VZV IgG assessment, 90.8% of all patients had specific anti-VZV antibodies at ASCT. Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation (P=0.009). Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ (P=0.007). Our data indicate that VZV reactivation after ASCT is a frequent event carrying a significant disease burden and it is associated with improved survival. Low levels of specific VZV antibodies at ASCT suggest increased vulnerability for VZV reactivation.


Asunto(s)
Anticuerpos Antivirales/sangre , Herpes Zóster , Herpesvirus Humano 3/fisiología , Mieloma Múltiple , Trasplante de Células Madre , Activación Viral , Adulto , Anciano , Autoinjertos , Supervivencia sin Enfermedad , Femenino , Herpes Zóster/sangre , Herpes Zóster/etiología , Herpes Zóster/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Mieloma Múltiple/mortalidad , Mieloma Múltiple/terapia , Mieloma Múltiple/virología , Tasa de Supervivencia
6.
Clin Microbiol Infect ; 20(7): 698-705, 2014 07.
Artículo en Inglés | MEDLINE | ID: mdl-24188136

RESUMEN

We analyzed the species distribution of Candida blood isolates (CBIs), prospectively collected between 2004 and 2009 within FUNGINOS, and compared their antifungal susceptibility according to clinical breakpoints defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) in 2013, and the Clinical and Laboratory Standards Institute (CLSI) in 2008 (old CLSI breakpoints) and 2012 (new CLSI breakpoints). CBIs were tested for susceptiblity to fluconazole, voriconazole and caspofungin by microtitre broth dilution (Sensititre® YeastOne™ test panel). Of 1090 CBIs, 675 (61.9%) were C. albicans, 191 (17.5%) C. glabrata, 64 (5.9%) C. tropicalis, 59 (5.4%) C. parapsilosis, 33 (3%) C. dubliniensis, 22 (2%) C. krusei and 46 (4.2%) rare Candida species. Independently of the breakpoints applied, C. albicans was almost uniformly (>98%) susceptible to all three antifungal agents. In contrast, the proportions of fluconazole- and voriconazole-susceptible C. tropicalis and F-susceptible C. parapsilosis were lower according to EUCAST/new CLSI breakpoints than to the old CLSI breakpoints. For caspofungin, non-susceptibility occurred mainly in C. krusei (63.3%) and C. glabrata (9.4%). Nine isolates (five C. tropicalis, three C. albicans and one C. parapsilosis) were cross-resistant to azoles according to EUCAST breakpoints, compared with three isolates (two C. albicans and one C. tropicalis) according to new and two (2 C. albicans) according to old CLSI breakpoints. Four species (C. albicans, C. glabrata, C. tropicalis and C. parapsilosis) represented >90% of all CBIs. In vitro resistance to fluconazole, voriconazole and caspofungin was rare among C. albicans, but an increase of non-susceptibile isolates was observed among C. tropicalis/C. parapsilosis for the azoles and C. glabrata/C. krusei for caspofungin according to EUCAST and new CLSI breakpoints compared with old CLSI breakpoints.


Asunto(s)
Antifúngicos/farmacología , Candida/clasificación , Candida/efectos de los fármacos , Candidemia/epidemiología , Candidemia/microbiología , Candida/aislamiento & purificación , Caspofungina , Farmacorresistencia Fúngica , Equinocandinas/farmacología , Fluconazol/farmacología , Lipopéptidos , Pruebas de Sensibilidad Microbiana , Estudios Prospectivos , Suiza/epidemiología , Voriconazol/farmacología
7.
Infection ; 39(3): 255-8, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21509423

RESUMEN

Actinomyces europaeus was first described in 1997 as a new species causing predominantly skin and soft-tissue infections. Mastitis due to A. europaeus is an unusual condition. This article reports a case of primary breast abscess caused by A. europaeus in a postmenopausal woman.


Asunto(s)
Absceso/microbiología , Actinomyces/aislamiento & purificación , Actinomyces/patogenicidad , Enfermedades de la Mama/microbiología , Absceso/tratamiento farmacológico , Absceso/patología , Actinomyces/genética , Anciano , Enfermedades de la Mama/tratamiento farmacológico , Enfermedades de la Mama/patología , Femenino , Humanos , ARN Ribosómico 16S/genética , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones de los Tejidos Blandos/microbiología , Infecciones de los Tejidos Blandos/patología , Resistencia betalactámica
8.
Clin Microbiol Infect ; 17(12): 1859-67, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21199154

RESUMEN

Zygomycosis is an important emerging fungal infection, associated with high morbidity and mortality. The Working Group on Zygomycosis of the European Confederation of Medical Mycology (ECMM) prospectively collected cases of proven and probable zygomycosis in 13 European countries occurring between 2005 and 2007. Cases were recorded by a standardized case report form, entered into an electronic database and analysed descriptively and by logistic regression analysis. During the study period, 230 cases fulfilled pre-set criteria for eligibility. The median age of the patients was 50 years (range, 1 month to 87 years); 60% were men. Underlying conditions included haematological malignancies (44%), trauma (15%), haematopoietic stem cell transplantation (9%) and diabetes mellitus (9%). The most common manifestations of zygomycosis were pulmonary (30%), rhinocerebral (27%), soft tissue (26%) and disseminated disease (15%). Diagnosis was made by both histology and culture in 108 cases (44%). Among 172 cases with cultures, Rhizopus spp. (34%), Mucor spp. (19%) and Lichtheimia (formerly Absidia) spp. (19%) were most commonly identified. Thirty-nine per cent of patients received amphotericin B formulations, 7% posaconazole and 21% received both agents; 15% of patients received no antifungal therapy. Total mortality in the entire cohort was 47%. On multivariate analysis, factors associated with survival were trauma as an underlying condition (p 0.019), treatment with amphotericin B (p 0.006) and surgery (p <0.001); factors associated with death were higher age (p 0.005) and the administration of caspofungin prior to diagnosis (p 0.011). In conclusion, zygomycosis remains a highly lethal disease. Administration of amphotericin B and surgery, where feasible, significantly improve survival.


Asunto(s)
Cigomicosis/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Antifúngicos/administración & dosificación , Niño , Preescolar , Complicaciones de la Diabetes , Europa (Continente)/epidemiología , Femenino , Hongos/clasificación , Hongos/aislamiento & purificación , Neoplasias Hematológicas/complicaciones , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores de Riesgo , Distribución por Sexo , Análisis de Supervivencia , Heridas y Lesiones/complicaciones , Adulto Joven , Cigomicosis/mortalidad
9.
Vet Microbiol ; 149(3-4): 374-80, 2011 May 05.
Artículo en Inglés | MEDLINE | ID: mdl-21146334

RESUMEN

Mycobacterium tuberculosis is the main cause of human tuberculosis. Infection in companion animals is mainly acquired from close contact to a diseased human patient and hence rarely diagnosed in countries with low tuberculosis incidence rates. Therefore the general awareness of the disease might be low. Here we report the potential risk of infection for veterinary personnel with M. tuberculosis during the clinical and pathological examination of a dog with unexpected disseminated tuberculosis. The dog had presented with symptoms of a central nervous system disease; rapid deterioration prevented a complete clinical workup, however. Post-mortem examination revealed systemic mycobacteriosis, and M. tuberculosis was identified by PCR amplification of DNA extracts from paraffin-embedded tissue sections and spoligotyping. Contact investigations among the owners and veterinary personnel using an IFN-γ release assay indicated that the index dog did not infect humans during its lifetime. Serological and IFN-γ release assay results of one of two cats in direct contact with the index dog, however, suggested that transmission of M. tuberculosis might have occurred. Importantly, all three pathologists performing the necropsy on the dog tested positive. Accidental infection was most likely due to inhalation of M. tuberculosis containing aerosols created by using an electric saw to open the brain cavity. As a consequence routine necropsy procedures have been adapted and a disease surveillance program, including tuberculosis, has been initiated. Our results highlight the importance of disease awareness and timely diagnosis of zoonotic infectious agents in optimizing work safety for veterinary personnel.


Asunto(s)
Enfermedades de los Perros/diagnóstico , Mycobacterium tuberculosis/aislamiento & purificación , Exposición Profesional , Tuberculosis/transmisión , Tuberculosis/veterinaria , Zoonosis/transmisión , Adulto , Animales , Autopsia , Enfermedades de los Gatos/diagnóstico , Enfermedades de los Gatos/microbiología , Enfermedades de los Gatos/transmisión , Gatos , Trazado de Contacto , ADN Bacteriano/genética , Enfermedades de los Perros/microbiología , Enfermedades de los Perros/transmisión , Perros , Femenino , Humanos , Masculino , Mycobacterium tuberculosis/genética , Factores de Riesgo , Tuberculosis/diagnóstico , Tuberculosis/microbiología , Adulto Joven , Zoonosis/microbiología
10.
Clin Microbiol Infect ; 17(9): 1366-71, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20950331

RESUMEN

Invasive aspergillosis (IA) is a live-threatening opportunistic infection that is best described in haematological patients with prolonged neutropenia or graft-versus-host disease. Data on IA in non-neutropenic patients are limited. The aim of this study was to establish the incidence, disease manifestations and outcome of IA in non-neutropenic patients diagnosed in five Swiss university hospitals during a 2-year period. Case identification was based on a comprehensive screening of hospital records. All cases of proven and probable IA were retrospectively analysed. Sixty-seven patients were analysed (median age 60 years; 76% male). Sixty-three per cent of cases were invasive pulmonary aspergillosis (IPA), and 17% of these were disseminated aspergillosis. The incidence of IPA was 1.2/10 000 admissions. Six of ten cases of extrapulmonary IA affected the brain. There were six cases of invasive rhinosinusitis, six cases of chronic pulmonary aspergillosis, and cases three of subacute pulmonary aspergillosis. The most frequent underlying condition of IA was corticosteroid treatment (57%), followed by chronic lung disease (48%), and intensive-care unit stays (43%). In 38% of patients with IPA, the diagnosis was established at autopsy. Old age was the only risk factor for post-mortem diagnosis, whereas previous solid organ transplantation and chronic lung disease were associated with lower odds of post-mortem diagnosis. The mortality rate was 57%.


Asunto(s)
Aspergilosis/epidemiología , Infecciones Oportunistas/epidemiología , Corticoesteroides/uso terapéutico , Factores de Edad , Anciano , Análisis de Varianza , Antifúngicos/uso terapéutico , Aspergilosis/sangre , Aspergilosis/tratamiento farmacológico , Femenino , Hospitales de Enseñanza , Humanos , Aspergilosis Pulmonar Invasiva/sangre , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Aspergilosis Pulmonar Invasiva/epidemiología , Masculino , Persona de Mediana Edad , Neutropenia/epidemiología , Neutropenia/microbiología , Infecciones Oportunistas/sangre , Infecciones Oportunistas/tratamiento farmacológico , Estudios Retrospectivos , Factores de Riesgo , Estadísticas no Paramétricas , Suiza/epidemiología
12.
Klin Monbl Augenheilkd ; 227(4): 257-61, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20408069

RESUMEN

PURPOSE: The aim of this study was to evaluate the antibiotic treatment of postoperative endophthalmitis with combined systemic meropenem and linezolid. METHODS: A retrospective analysis of endophthalmitis treated with systemic meropenem and linezolid compared to conventional systemic antibiotics by evaluation of outcome and adverse effects was carried out. RESULTS: 26 patients with unilateral postoperative endophthalmitis with a systemic combination regimen of meropenem (2 g TID, mean duration of treatment 5.5 days) and linezolid (600 mg BID, mean duration of treatment 8.9 days) (group 1, mean follow-up time 140 days) were included in this study and compared to 45 postoperative endophthalmitis patients treated with conventional systemic antibiotics (group 2; mean follow-up time 320 days). In group 1, 69.2 % of eyes additionally received intravitreal amikacin and vancomycin (vs. 24.4 % in group 2; p < 0.001), in 92.3 % pars plana vitrectomy was performed (vs. 68.9 % in group 2, p = 0.047). Mean best corrected visual acuity improved from a baseline of 1.76 logMar for group 1 and 1.83 logMar for group 2 to 0.91 logMar (p = 0.0001) and 0.90 logMar (p < 0.0001), respectively, at the end of the follow-up, revealing no significant differences between the two groups at any time point (p > 0.05). Ocular complications were observed in 34.6 % of eyes in group 1 (vs. 37.8 % in group 2; p > 0.05). Adverse drug effects occurred significantly more frequently in group 1 (26.9 % vs. 4.4 % p = 0.02). CONCLUSION: In spite of the reported better penetration through the blood-ocular barrier and the broader antibacterial spectrum of meropenem and linezolid, no benefit in outcome was found in the present study. In contrast, adverse effects and costs of the combination regimen were significantly higher.


Asunto(s)
Acetamidas/administración & dosificación , Endoftalmitis/tratamiento farmacológico , Endoftalmitis/etiología , Procedimientos Quirúrgicos Oftalmológicos/efectos adversos , Oxazolidinonas/administración & dosificación , Tienamicinas/administración & dosificación , Anciano , Antibacterianos/administración & dosificación , Antiinfecciosos/administración & dosificación , Combinación de Medicamentos , Endoftalmitis/prevención & control , Femenino , Humanos , Linezolid , Masculino , Meropenem , Estudios Retrospectivos , Resultado del Tratamiento
13.
Praxis (Bern 1994) ; 98(10): 547-50, 2009 May 13.
Artículo en Alemán | MEDLINE | ID: mdl-19424951

RESUMEN

A 22-year-old man with pre-existing aortic valve disease contracted acute lactobacillus endocarditis six weeks after a dental procedure despite adequate prophylaxis. We discuss the limitations of prophylaxis for infective endocarditis in use until the end of 2008 and describe the new updated guidelines. We also explain the treatment of lactobacillus endocarditis and speculate on possible health risks of the increasing use of lactobacillus-containing dairy products, especially in immune-compromised patients.


Asunto(s)
Estenosis de la Válvula Aórtica/congénito , Válvula Aórtica/anomalías , Bacteriemia/etiología , Endocarditis Bacteriana/etiología , Infecciones por Bacterias Grampositivas/etiología , Lactobacillus , Complicaciones Posoperatorias/etiología , Extracción Dental , Yogur/efectos adversos , Yogur/microbiología , Válvula Aórtica/cirugía , Insuficiencia de la Válvula Aórtica/complicaciones , Insuficiencia de la Válvula Aórtica/diagnóstico por imagen , Estenosis de la Válvula Aórtica/cirugía , Bacteriemia/microbiología , Ecocardiografía Transesofágica , Endocarditis Bacteriana/microbiología , Humanos , Masculino , Complicaciones Posoperatorias/microbiología , Factores de Riesgo , Adulto Joven
14.
Infection ; 36(3): 274-8, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18084716

RESUMEN

Skeletal tuberculosis is now uncommon in developed countries. In immunocompromised patients--particularly in the HIV-infected--who present with subacute or chronic joint pain refractory to conventional treatment, osteoarticular tuberculosis should still be included in the differential diagnosis. We report on a lethal case of disseminated tuberculosis in an HIV-infected subject. Dissemination may have resulted from the implantation of an articular prosthesis in a knee joint with unsuspected osteoarticular tuberculosis. The diagnosis was established months later when the patient presented with far-advanced tuberculous meningitis, miliary tuberculosis of the lungs, femoral osteomyelitis and extended cold abscesses along the femoral shaft. Failure to respond to a conventional four-drug regimen is explained by the resistance pattern of his multi-drug resistant strain of Mycobacterium tuberculosis, which was only reported after the patient's death. This case illustrates the diagnostic challenges of osteoarticular tuberculosis and the consequences of a diagnostic delay in an HIV-infected individual.


Asunto(s)
Artroplastia de Reemplazo de Rodilla/efectos adversos , Articulación de la Rodilla/microbiología , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Resistente a Múltiples Medicamentos/complicaciones , Tuberculosis Osteoarticular/complicaciones , Tuberculosis Osteoarticular/cirugía , Resultado Fatal , Fémur/microbiología , Fémur/patología , Humanos , Articulación de la Rodilla/diagnóstico por imagen , Articulación de la Rodilla/cirugía , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/aislamiento & purificación , Osteomielitis/etiología , Osteomielitis/microbiología , Radiografía , Tuberculosis Meníngea/etiología , Tuberculosis Meníngea/microbiología , Tuberculosis Miliar/etiología , Tuberculosis Miliar/microbiología , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Osteoarticular/microbiología , Tuberculosis Pulmonar/etiología , Tuberculosis Pulmonar/microbiología
18.
Clin Microbiol Infect ; 12(4): 331-7, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16524409

RESUMEN

Cerebrospinal fluid (CSF) shunts carry a high risk of complications. Infections represent a major cause of shunt failure. Diagnosis and therapy of such infections are complicated by the formation of bacterial biofilms attached to shunt surfaces. This study correlated the pathophysiology and clinical course of biofilm infections with microscopical findings on the respective shunts. Surface irregularities, an important risk-factor for shunt colonisation with bacteria, were found to increase over time because of silicone degradation. Scanning electron-microscopy (SEM) documented residual biological material (dead biofilm), which can further promote extant bacterial adhesion, on newly manufactured shunts. Clinical course and SEM both documented bacterial dissemination against CSF flow and the monodirectional valve. In all cases, biofilms grew on both the inner and outer surfaces of the shunts. Microscopy and conventional culture detected all bacterial shunt infections. Analyses of 16S rDNA sequences using conserved primers identified bacteria in only one of three cases, probably because of previous formalin fixation of the samples.


Asunto(s)
Infecciones Bacterianas/diagnóstico , Biopelículas , Derivaciones del Líquido Cefalorraquídeo , Adolescente , Adulto , Bacterias/genética , Bacterias/aislamiento & purificación , Infecciones Bacterianas/microbiología , ADN Bacteriano/análisis , ADN Ribosómico/análisis , Femenino , Humanos , Masculino , Microscopía Electrónica de Rastreo , ARN Ribosómico 16S/genética
19.
Infection ; 34(1): 35-8, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16501901

RESUMEN

BACKGROUND: Dysphagia is seldom caused by tetanus; however, it is a common symptom of tetanus. Treating patients with tetanus is a rare event in industrialized countries and awareness is needed to recognize early signs of this serious disease. In Switzerland, the most recently reported tetanus cases occurred in elderly women with insufficient seroprotection. PATIENTS: We report on three elderly women presenting with dysphagia as an initial symptom of tetanus. RESULTS: Generalized tetanus was diagnosed in two patients upon admission, the third presented with cephalic tetanus with secondary generalization. All three patients had undetectable levels of tetanus antibodies and had no documented prior tetanus immunizations. Cultures of wound swabs grew Clostridium tetani in all cases. Electromyography was highly suggestive for tetanus in two patients. Treatment involved mechanical ventilation, intravenous benzodiazepine and metronidazole therapy, and active and passive tetanus immunization. The disease had a favorable outcome in two cases and was fatal in one. CONCLUSION: Tetanus remains a threat in patients with insufficient seroprotection and efforts are needed to improve tetanus immunization in these individuals. Tetanus should be considered in the differential diagnosis of dysphagia.


Asunto(s)
Trastornos de Deglución/diagnóstico , Trastornos de Deglución/etiología , Tétanos/complicaciones , Tétanos/diagnóstico , Anciano , Anciano de 80 o más Años , Clostridium tetani/aislamiento & purificación , Resultado Fatal , Femenino , Humanos , Inmunización , Rodilla/patología , Tétanos/terapia , Toxoide Tetánico/administración & dosificación , Resultado del Tratamiento , Trismo/patología , Infección de Heridas/complicaciones , Infección de Heridas/diagnóstico , Infección de Heridas/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...